Published:17/06/2020
Andreas Meliniotis, Director of Device Development at Vectura, discusses the key considerations to reduce risk when developing a DPI product from early clinical trials through to scale-up, and provides insights for both novel and generic development programs.
Register here: https://bit.ly/30qtaz4
Attachments
- Original document
- Permalink
Disclaimer
Vectura Group plc published this content on 17 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 June 2020 12:31:09 UTC